ACAD Reiterated by Needham -- Price Target Maintained at $35

gurufocus.com · 2026-10-19

Acadia Pharmaceuticals: Analyst Rating Update and Valuation Insights On October 19, 2026, Acadia Pharmaceuticals (ACAD) received a rating update from Needham

TickrTrends take: Needham's maintained price target of 35 dollars for ACAD suggests analyst confidence in the company's fundamentals, yet TickrTrends currently derives an Overvalued assessment for the Healthcare sector company. The persistence of this price target amid an Overvalued designation indicates a potential disconnect between traditional analyst valuations and current market pricing that investors focused on valuation metrics may want to monitor. A valuation-conscious reader should track whether market conditions or company fundamentals shift to narrow the gap between the analyst target and the current valuation assessment.

Read the full story at gurufocus.com →